Testing for Mechanically Imprinted Drug Resistance in Pancreatic Ductal Adenocarcinoma

Abstract

HYPOTHESIS AND COLLABORATIVE EXPERIMENTAL CHALLENGE Testing for Mechanically Imprinted Drug Resistance in Pancreatic Ductal Adenocarcinoma An Integrative Hypothesis Linking PIEZO1 METTL14 YAP1 BRG1 NRF2 and SLC7A11 Bouchelit Mohammed El Amin Founder and Scientific Lead HISTAMOS Independent Research Program Germany www.histamos.com | contact@histamos.com Manuscript type Hypothesis article and open experimental challenge Version Version 1.2 13 September 2026 Evidence basis Synthesis of published studies no new experimental data Clinical status Preclinical hypothesis not a diagnostic or treatment recommendation PUBLIC DISCUSSION DRAFT Prepared for scholarly critique, collaborative testing, and versioned deposition Abstract Pancreatic ductal adenocarcinoma is embedded in a mechanically active fibrotic environment that can alter drug response. Patient-derived pancreatic cancer organoids have shown stiffness-associated resistance that reversed after transfer to a softer matrix. This is the strongest directly human-derived result relevant to the present model, and it supports reversible environmental adaptation more directly than persistent cellular memory. Separate studies connect matrix stiffness to PIEZO1-dependent metabolic adaptation, to a reciprocal METTL14-YAP1 program associated with mechanical persistence and matrix remodeling, and to a BRG1-NRF2-SLC7A11 antioxidant program that suppresses ferroptotic vulnerability after chemotherapy-induced stromal change. These studies use different systems and do not establish one continuous mechanism. We therefore frame the proposal as a stage-gated hypothesis. The first experiment asks only whether prolonged or repeated mechanical priming leaves a drug-resistant state in the same tracked lineage after verified removal of matrix and fibroblast-derived signals and after matching the intracellular active drug species. Failure at this stage rejects the autonomous-memory component and stops downstream pathway ordering. Only if post-clearance persistence is demonstrated should a second stage test whether PIEZO1 acts predominantly during induction, METTL14-YAP1 is required after the initiating signal has decayed, and BRG1-NRF2-SLC7A11 provides a separable redox-survival output. A third stage tests durability after verified intervention inactivity, repeated drug challenge, and re-priming. The design includes qualified perturbation tools, active-species and target-effect clearance checks, functional rather than abundance-only pathway measurements, longitudinal lineage tracking, cell-matrix relay controls, reverse and concurrent sequence controls, molecular rescue, delayed regrowth across multiple recovery times, and independent replication. It distinguishes reversible adaptation, residual environmental or pharmacological carryover, exposure artifacts, clonal selection, continuous mechanosensing, persistent same-lineage state, acute sensitization, and durable reset. This article contains no new efficacy data and supports no clinical use. Keywords pancreatic ductal adenocarcinoma matrix stiffness mechanical memory chemoresistance PIEZO1 YAP1 ferroptosis patient-derived organoids Central proposition If resistance persists in the same tracked lineage after the conditioning environment has been cleared and active intracellular drug exposure has been matched, PIEZO1 may act predominantly during induction, METTL14-YAP1 may maintain the post-clearance state, and BRG1-NRF2-SLC7A11 may supply a separable redox-survival output. The persistence test precedes every pathway assignment. Plain Language Summary Pancreatic tumors are often surrounded by unusually dense and stiff tissue. Laboratory studies indicate that stiffness can make pancreatic cancer cells less responsive to drugs. The unresolved question is whether cells simply respond while the stiff environment is present, or whether some cells retain a biological memory after that environment is removed. This paper proposes that three connected processes may be involved. A pressure-sensing channel called PIEZO1 may detect the original mechanical change. A feedback relationship involving METTL14 and YAP1 may help preserve an adapted state. A separate antioxidant program involving BRG1, NRF2, and SLC7A11 may then protect cells from treatment-related oxidative damage. The study is deliberately divided into stages. First, it follows the same cell lineages before, during, and after controlled stiffness and asks whether resistance survives complete removal of the conditioning source while active drug exposure is kept equivalent. If it does not, the memory proposal stops there. Only if it does should later stages interrupt the candidate processes at different times, prove that each intervention is no longer exerting a direct effect, and expose the cells to treatment again. This design distinguishes reversible adaptation, selection of a pre-existing clone, leftover environmental or drug effects, continuous sensing, and a persistent cell state. The work is a research challenge for laboratories. It is not evidence that any combination should be given to patients. Introduction Pancreatic ductal adenocarcinoma develops within a desmoplastic microenvironment containing fibroblasts, extracellular matrix, immune cells, soluble signals, and marked spatial variation in mechanics. The matrix is not a passive scaffold. It can modify cell shape, signaling, metabolism, drug transport, and cell-state composition. Yet the clinical and experimental meaning of a stiff tumor remains unsettled because stromal components can support resistance in one setting and restrain tumor progression in another. Studies that reduce matrix or fibroblast content in mouse models have sometimes accelerated disease, whereas other approaches that modify specific physical barriers have improved drug delivery [12-14]. A useful hypothesis must therefore avoid equating all stroma with one harmful function. Most drug-response experiments compare cells kept continuously in soft or stiff matrices. Such experiments can establish a current environmental effect, but they do not establish memory. A resistant phenotype measured while the stiff matrix remains present could reflect ongoing mechanosensing, altered diffusion, altered proliferation, a transient stress response, selection of a pre-existing clone, or a persistent state. These possibilities imply different biology and different intervention strategies. The central need is a temporal experiment in which the original mechanical input is removed and verified as absent before resistance is measured again. Several recent PDAC studies now make that experiment both plausible and timely. Engineered matrices have demonstrated stiffness-associated chemoresistance in patient-derived organoids [1]. Three-dimensional cell-line models have linked stiffness to PIEZO1-dependent glycolytic adaptation [2]. Other models have linked stiffness to m6A-dependent YAP1 regulation and to reciprocal METTL14-YAP1 signaling associated with mechanical memory [3,4]. A 2026 study further connected gemcitabine-induced senescence, fibroblast activation, stromal stiffening, PIEZO1 signaling, and BRG1-NRF2-SLC7A11-dependent antioxidant adaptation [5]. The cited studies do not share the same donors, matrices, exposure histories, perturbations, or endpoints. They cannot be combined as if they were one experiment. They can, however, motivate one decisive test. Operational Definitions Term Public experimental meaning Stiffness-conditioned resistance Reduced drug sensitivity measured during or immediately after exposure to a mechanically stiff environment. Post-clearance persistence Resistance detected after the stiff matrix, fibroblast-conditioned signals, and other initiating inputs have been removed and their clearance has been verified, with active intracellular challenge-drug exposure matched across groups. Mechanical memory A persistent state within the same tracked lineage that outlasts the initiating mechanical input and is not explained by residual exposure or replacement by a different clone. Functional redox output The antioxidant and ferroptosis-suppressing activity that directly supports survival during a defined treatment challenge. Acute sensitization Improved drug response only while an intervention remains active, without evidence that the underlying resistant state has been removed. Durable reset Loss of the resistant phenotype that remains after verified intervention inactivity, recovery, and repeated challenge, without disproportionate cell loss or clone replacement. Evidence Supporting the Individual Links Stiffness and Drug Response in Patient Derived Organoids LeSavage and colleagues used engineered matrices to separate matrix stiffness from other microenvironmental variables in pancreatic cancer organoids derived from three patients [1]. Higher stiffness was associated with resistance across several clinically relevant agents. Their analyses argued against a purely genetic clonal explanation and implicated CD44-hyaluronan signaling and drug-efflux behavior. Importantly, sensitivity returned after organoids were moved from stiff to soft matrices. This is the strongest directly human-derived evidence in the present chain, but it supports reversible environmental adaptation more clearly than autonomous memory. The result is therefore both a foundation and a counterweight: any proposed persistent state must exceed this reversible baseline under explicitly defined priming conditions. PIEZO1 and Early Mechanical Adaptation Pan and colleagues modeled PDAC cells in three-dimensional matrices and reported that higher stiffness increased glycolysis and gemcitabine resistance together with PIEZO1-dependent calcium signaling [2]. Pharmacological activation and inhibition supported a causal